• 13Jan

    Bavarian Nordic’s Case Against Oxford BioMedica

    Medical News

    Bavarian Nordic owns several United States patents relating to an attenuated strain of the company’s core technology, MVA-BN®, which is the basis for its smallpox vaccine, IMVAMUNE®. MVA-BN® also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted three US patents as a basis for its infringement action.

    Read more

    Posted by News @ 9:20 am

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.